Atrial Fibrillation

>

Latest News

Novel Factor XI Inhibitor Abelacimab Found Superior to Rivaroxaban in Phase 2b Trial with High-Risk Cohort image Marc Sabatine, MD, MPH, Courtesy of BWH
Novel Factor XI Inhibitor Abelacimab Found Superior to Rivaroxaban in Phase 2b Trial with High-Risk Cohort

September 19th 2023

The AZALEA-TIMI 71 trial was stopped early due to an "overwhelming reduction" in a composite endpoint of major bleeding events compared to rivaroxaban standard of care.

Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes
Daily Dose: Worldwide Burden of Atrial Fibrillation Doubled Over 30 Years

September 12th 2023

Worldwide Burden of Atrial Fibrillation More Than Doubled Over 30 Years: Global Analysis / image credit ©TuMeggy/stock.adobe.com
Worldwide Burden of Atrial Fibrillation More Than Doubled Over 30 Years: Global Analysis

September 1st 2023

image credit pills money ©alex mlx/stock.adobe.com
Biden Administration Announces First 10 Prescription Drugs Slated for Price Negotiations

August 29th 2023

Frail Elderly at High Risk of Bleeding Following VKA-DOAC Switch: Surprise Outcome Shared at ESC Congress  Image credit © Lightspring/Shutterstock.com
Frail Elderly at High Risk of Bleeding Following VKA-DOAC Switch: Surprise Outcome Shared at ESC Congress

August 28th 2023

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.